Publications Histiocytoses

Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.

Response to trametinib of histiocytosis with an activating PTPN11 mutation.

Diabetes Mellitus, Extreme Insulin Resistance, and Hypothalamic-Pituitary Langerhans Cells Histiocytosis.

Endocrine manifestations in a cohort of 63 adulthood and childhood onset patients with Langerhans Cell Histiocytosis.

Erdheim-Chester Disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1.

RASA1 loss in a BRAF-mutated Langerhans cell sarcoma: a mechanism of resistance to BRAF inhibitor.

Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors.

Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study.

Highly sensitive methods are required to detect mutations in histiocytoses

Langerhans Cell Histiocytoma: A Benign Histiocytic Neoplasm of Diverse Lines of Terminal Differentiation.

Long-bones involvement in generalized crystal-storing histiocytosis.

Glomeruloid haemangioma: a possible consequence of elevated VEGF in POEMS and Erdheim-Chester disease.

Hypoalphalipoproteinemia and BRAF^V600E Mutation Are Major Predictors of Aortic Infiltration in the Erdheim-Chester Disease.

Cladribine-related immunosuppression may have fostered graft-versus-host disease after lung transplant for pulmonary Langerhans cell histiocytosis.

Highly sensitive methods are required to detect mutations in histiocytoses.

Langerhans Cell Histiocytoma: A Benign Histiocytic Neoplasm of Diverse Lines of Terminal Differentiation.

Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment.

Hypoalphalipoproteinemia and BRAFV600E Mutation Are Major Predictors of Aortic Infiltration in the Erdheim-Chester Disease.

BRAF V600E mutation detected in a case of Rosai-Dorfman disease.

Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease.

Phenotypes and survival in Erdheim-Chester disease: results from a 165-patient cohort

Efficacy of infliximab in the treatment of Erdheim-Chester disease.

How I manage pulmonary Langerhans cell histiocytosis. Lorillon G et al. Eur Respir Rev. 2017 Sep 6;26(145).

Current understanding and management of pulmonary Langerhans cell histiocytosis. Vassallo R et al. Thorax. 2017 Oct;72(10):937-945.

Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study. Tazi A et al.  Orphanet J Rare Dis. 2017 May 22;12(1):95.

New somatic BRAF splicing mutation in Langerhans cell histiocytosis. Héritier S et al. Mol Cancer. 2017 Jul 6;16(1):115.

Circulating cell-free BRAFV600E as a biomarker in children with Langerhans cell histiocytosis. Héritier S et al. Br J Haematol. 2017 Aug;178(3):457-467.

Erdheim-Chester disease: the “targeted” revolution. Vaglio A et al. Blood. 2017 Sep 14;130(11):1282-1284.

Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. Durham BH et al. Blood. 2017 Jul 13;130(2):176-180.

Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). Cohen Aubart F et al. Blood. 2017 Sep 14;130(11):1377-1380.

High prevalence of myeloid neoplasms in adults with non–Langerhans cell histiocytosis. Papo M et al. Blood. 2017 Aug 24;130(8):1007-1013.

Histiocytoses langerhansienne de l'adulte La Revue de Médecine Interne ; 36(10):658-67 ; Octobre 2015

The natural history of adult pulmonary Langerhans cell histiocytosis: a prospective multicentre study.